Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

The Road Ahead

As we head into 2020, closing out a decade punctuated by an ever-changing healthcare dynamic shaped by scientific discoveries, technological breakthroughs, innovation at every level, as well as global geopolitical forces, there is no doubt that the status quo is no longer a business mantra.

This month’s cover story is a perfect example of the saying, to paraphrase Marshall Goldsmith, what got us here won’t get us there, in terms of drug development. The dynamic between small biotech and pharmaceutical companies and their larger company peers is changing — smaller more agile operations buoyed by large R&D and commercial operations and deep pockets. As we report, visionary thought leaders such as Bernard Munos of InnoThink and the Milken Institute and Paul Stoffels, M.D., vice chairman of the executive committee and chief scientific officer, Johnson & Johnson, have been advocating for years that the blockbuster model is broken and unsustainable. They have been pushing for a change in the R&D model that will drive more transformational innovation. That day of transformation may be upon us, as small biotech and large pharma companies have started to work synergistically to create a faster, more cost-effective way to bring new treatments to market.

Companies, such as Novartis, as reported by Fabrice Chouraqui, former president of Novartis Pharmaceuticals US, in this month’s issue are turning creative thinking into tangible output. He believes innovation is about changing the status quo to create meaningful value to customers. And that requires an innovative company culture built on purpose, resilience, and personal accountability.

Breakthrough science, such as what is happening in the RNAi field, is changing our understanding of how genes are regulated in cells. RNAi, which has the potential to change the landscape of medicine and represents a new approach to drug discovery and development, is just beginning to enter the golden age, according to Christopher Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals. (Arrowhead and its RNAi technology is just one of several companies covered in this issue.) He says after two decades of intensive study and development, this modality is increasingly being accepted as a reliable and powerful way to treat a variety of diseases.

As always, innovation without making an appreciable and positive significance to patients is just change for the sake of change. In this issue, we also cover the importance of communicating high science and how medical storytelling can improve the patient journey.

As we venture into the last year of this decade, we can expect more of …well everything. Cheers to the ride ahead.

Taren Grom, Editor


Their word…

Denise Myshko
Managing Editor

RNA interference is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development.

Robin Robinson
Senior Editor

Small pharma and biotechs are driving innovation, accounting for 63% of new drug approvals over the past five years.

Kim Ribbink
Features Editor

The question of who owns patients’ data is a complex one, and highlights the need for ethics and reciprocity to advance goals around drug discovery, health interventions, and improving outcomes.


February 2020

New Pipeline Pathways
Agile Marketing
Oncology Update
Unconventional Alliances
Chief Innovation Officers
R&D Influencers
Showcase: Outsourcing
Showcase: Rare Disease



The forum for the industry executive

Volume 20 • Number 1
Publisher Lisa Banket
Editor Taren Grom
Creative Director Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2020
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Twenty, Number One

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVOICE Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVOICE at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVOICE retains all rights on material published in PharmaVOICE for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVOICE is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

Letters …

Send your letters to feedback@pharma­voice.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.

Posted in:

Post a Comment

You must be logged in to post a Comment.